Top 10 Best Recovery Peptides for Research (2026)

“Recovery peptide” isn’t an established medical category it’s a term used online to describe peptides investigated for tissue repair, inflammation, cell migration, and regeneration. The peptides with the most substantial preclinical research interest in 2026 include BPC-157, TB-500 (thymosin beta-4), GHK-Cu, KPV, LL-37, MOTS-c, and thymosin alpha-1, among others. “Best” here reflects research volume and interest, not proven clinical effectiveness most evidence for these compounds is still preclinical, not established human clinical evidence.

What Are Recovery Peptides?

“Recovery peptide” is marketing and community shorthand, not a regulatory or scientific classification. It’s commonly applied to short amino acid chains studied for roles in processes like angiogenesis (new blood vessel formation), fibroblast activity, collagen synthesis, cell migration, and inflammatory signaling mechanisms relevant to how tissue repairs itself. None of that means a given peptide is a proven treatment.

It’s useful to keep four categories distinct:

• Experimental / mechanistic research cell-culture and biochemical studies
• Preclinical research animal models
• Human clinical research studies in people, ranging from small early-phase work to larger controlled trials
• Approved medical treatments drugs that have gone through FDA review and been approved for a specific indication

Most peptides discussed as “recovery peptides” including every one on this list fall into the first two categories. None are FDA-approved for tissue repair or recovery use, and none should be treated as if they were.

Hotspan note: This article is educational, evidence-focused content about published research it is not a product guide. If you’re researching any of these peptides for laboratory use, Hotspan sells BPC-157 and TB-500 as RUO research compounds, documented separately with their own testing information. These products are not intended for human use and are not a substitute for medical treatment.

How We Ranked This List

Criterion	Weight
Relevant research volume	20%
Study quality	20%
Human evidence	20%
Relevance to recovery/tissue research	15%
Research consistency	10%
Mechanistic evidence	10%
Safety data	5%

This ranking reflects the strength and relevance of published research interest not therapeutic effectiveness, and not a recommendation for use. A peptide with a larger body of animal research is not automatically superior to one with less; what matters is whether the evidence, at whatever stage it’s at, is well-designed and consistent.

Evidence Levels Used in This Article

• Level 1 — Mechanistic/laboratory: cellular or biochemical research
• Level 2 — Animal/preclinical: research conducted in animal models
• Level 3 — Early human evidence: small human studies, case reports, or early clinical research
• Level 4 — Controlled human evidence: well-designed clinical studies
• Level 5 — Established clinical evidence: multiple high-quality human studies supporting a specific clinical use

Most peptides on this list sit at Level 1 or 2. Where a peptide has any Level 3 or higher evidence, it’s stated explicitly.

Recovery Peptide Comparison Table

“Not publicly disclosed” and “human clinical evidence is currently limited or unavailable for this specific recovery application” both apply liberally throughout this list treat every entry as preclinical-stage research interest unless stated otherwise.

#1. BPC-157

What is it?

A synthetic peptide derived from a fragment of a protein found in human gastric juice, consisting of 15 amino acids. See our BPC-157 supplier guide for sourcing and COA considerations if you’re evaluating research-grade material.

Why is it being researched for recovery?

Animal studies have proposed mechanisms involving nitric oxide-mediated angiogenesis and modulation of growth factor pathways relevant to tissue repair.

What does the research show?

BPC-157 has the largest body of preclinical literature among peptides in this category, studied in animal models across tendon, ligament, muscle, gut, and nervous tissue. Effects reported in these models include enhanced fibroblast migration toward injury sites in wound models.

What tissues have been studied?

Tendon, ligament, muscle, gastrointestinal tissue, and nerve tissue all in animal models.

Human evidence: Human clinical evidence is currently limited or unavailable for tissue-repair applications specifically.

Evidence level: Preclinical (Level 2)

Key limitations:

• The FDA’s review of BPC-157 as a compounding bulk substance found available safety information insufficient for the routes evaluated, citing potential immunogenicity and peptide-related impurities as concerns. See the FDA’s Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks page for the current listing.
• Regulatory status has been in flux BPC-157 was added to the FDA’s Category 2 bulk-substance list in September 2023, with a 2026 Pharmacy Compounding Advisory Committee review and HHS reclassification process affecting some peptides in this category; confirm current status before relying on any regulatory claim
• Most positive findings are from rodent injury models, which don’t reliably predict human outcomes

#2. TB-500 / Thymosin Beta-4

What is it?

TB-500 is a synthetic peptide fragment related to thymosin beta-4 (Tβ4), a naturally occurring protein involved in cell structure and movement. “TB-500,” “TB-4,” and “thymosin beta-4” are related but not always interchangeable terms in the literature TB-500 specifically refers to a synthesized fragment. See our TB-500 supplier guide for sourcing and COA considerations if you’re evaluating research-grade material.

Why is it being researched for recovery?

Proposed mechanisms center on actin regulation (a protein involved in cell shape and movement), which researchers have linked to cell migration and angiogenesis relevant to wound and soft-tissue repair.

What does the research show?

Animal and cell-based research has investigated thymosin beta-4-related compounds in wound-healing and soft-tissue models, with proposed roles in cell migration and blood vessel formation.

What tissues have been studied?

Soft tissue and wound models, predominantly in animal research.

Human evidence: Human clinical evidence is currently limited or unavailable for recovery applications specifically.

Evidence level: Preclinical (Level 2)

Key limitations:

• FDA materials reviewing TB-500-related bulk substances (listed as “Thymosin Beta-4, Fragment (LKKTETQ)” on the FDA’s Category 2 bulks list) have noted limited human exposure information
• The FDA’s 2026 Pharmacy Compounding Advisory Committee process specifically evaluated BPC-157 and thymosin beta-4-related substances this reflects ongoing regulatory review, not approval or endorsement
• Distinguishing “TB-500” from other thymosin beta-4 fragments in cited research matters and is often glossed over in non-scientific sources

#3. GHK-Cu

What is it?

A naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) found in human plasma, studied for decades in skin biology.

Why is it being researched for recovery?

Its copper-binding properties are proposed to support collagen formation, antioxidant defense, and extracellular matrix remodeling processes relevant to skin and wound repair.

What does the research show?

The topical/dermatological literature on GHK-Cu is comparatively well-developed, and it appears in cosmetic formulations studied for skin remodeling. The injectable use case the form relevant to “recovery peptide” discussions has a much thinner, largely preclinical evidence base.

What tissues have been studied?

Skin extensively (topical); connective tissue to a lesser extent (injectable, preclinical).

Human evidence: Some human evidence exists for topical/cosmetic use; human clinical evidence for injectable use in tissue-repair/recovery contexts is currently limited.

Evidence level: Topical Level 3–4; injectable Level 1–2

Key limitations:

• FDA materials note limited human safety data for injectable GHK-Cu specifically, with potential concerns around immunogenicity, aggregation, and peptide-related impurities see the FDA’s Category 2 bulk substances list, which specifically flags GHK-Cu for injectable routes of administration
• Cosmetic/topical research findings should not be extrapolated to injectable use for musculoskeletal or soft-tissue recovery different formulation, different exposure, different evidence base

#4. KPV

What is it?

A short tripeptide (lysine-proline-valine) derived from a fragment of alpha-melanocyte-stimulating hormone (α-MSH), studied for anti-inflammatory and immune-modulating activity.

Why is it being researched for recovery?

Proposed to modulate inflammatory signaling, which is relevant to recovery processes where excess inflammation may slow tissue repair most notably studied in gut inflammation models.

What does the research show?

Preclinical research, largely in animal models of intestinal inflammation, has investigated KPV’s anti-inflammatory activity.

What tissues have been studied?

Gastrointestinal tissue primarily, in animal models.

Human evidence: Human clinical evidence is currently limited or unavailable for recovery-specific applications.

Evidence level: Preclinical (Level 2)

Key limitations:

• KPV was among the peptides reviewed in 2026 FDA compounding advisory discussions alongside BPC-157, TB-500, and others see the FDA’s Category 2 bulk substances list
• Most available research targets gut inflammation specifically, not musculoskeletal recovery the “recovery” framing for KPV is a broader extrapolation than the underlying research supports

#5. LL-37

What is it?

A human antimicrobial peptide, part of the innate immune system, studied for roles in wound healing alongside its antimicrobial function.

Why is it being researched for recovery

Proposed to support wound closure and modulate immune activity at injury sites, in addition to antimicrobial properties.

What does the research show?

Preclinical and some ex vivo human tissue research has investigated LL-37 in skin and wound models.

What tissues have been studied?

Skin and wound tissue.

Human evidence: Limited largely ex vivo tissue studies rather than in vivo human clinical trials for recovery use.

Evidence level: Preclinical (Level 2)

Key limitations:

• Research indicates LL-37’s effects are concentration-dependent, with cytotoxic effects reported at higher concentrations in vitro a meaningful safety consideration
• Most human-tissue research uses isolated cell or tissue samples, not living human subjects

#6. MOTS-c

What is it?

A mitochondrial-derived peptide involved in metabolic regulation.

Why is it being researched for recovery?

Proposed roles in mitochondrial and metabolic regulation have generated interest in muscle-related applications, though its research base is more metabolic than tissue-repair focused.

What does the research show?

Animal studies have investigated MOTS-c’s role in muscle metabolism and exercise-related physiology.

What tissues have been studied?

Muscle tissue, in animal models, with a metabolic rather than structural-repair focus.

Human evidence: Human clinical evidence is currently limited or unavailable for recovery applications specifically.

Evidence level: Preclinical (Level 2)

Key limitations:

• MOTS-c’s relevance to tissue “recovery” (as opposed to metabolic function) is largely inferred rather than directly studied
• Much of the interest in MOTS-c stems from exercise physiology research, not injury-recovery research specifically

#7. Thymosin Alpha-1

What is it?

A peptide with immune-modulating properties; approved as a pharmaceutical (marketed as Zadaxin in some countries) for indications like hepatitis B/C and as an immune adjunct, though not FDA-approved in the United States.

Why is it being researched for recovery?

Its established immune-modulating activity has led to interest in broader “recovery” applications, though this is largely extrapolated from its approved use cases rather than directly studied for tissue repair.

What does the research show?

Human clinical data exists for thymosin alpha-1’s approved indications (immune modulation in specific disease contexts) this is a peptide with genuinely stronger human evidence than most others on this list, but not for recovery/tissue-repair use specifically.

What tissues have been studied?

Immune system function broadly; not specifically musculoskeletal or soft tissue.

Human evidence: Yes, for its studied indications but “recovery” use is an extrapolation, not a studied endpoint.

Evidence level: Level 3–4 for its approved indications; effectively Level 1 for “recovery” use specifically, since that isn’t what the human trials studied

Key limitations:

• Not FDA-approved in the United States for any indication
• Strong human evidence for immune-modulation contexts doesn’t transfer automatically to “recovery” claims, which rest on a much thinner evidentiary basis

#8. Follistatin-344

What is it?

A peptide that inhibits myostatin, a protein that normally limits muscle growth.

Why is it being researched for recovery?

Myostatin inhibition is mechanistically linked to muscle growth signaling, generating interest in muscle-recovery applications.

What does the research show?

Animal research has investigated follistatin’s myostatin-inhibiting effects and downstream muscle growth signaling.

What tissues have been studied?

Muscle tissue, in animal models.

Human evidence: Human clinical evidence is currently limited or unavailable for recovery applications specifically.

Evidence level: Mechanistic to preclinical (Level 1–2)

Key limitations:

• The connection between myostatin inhibition and “recovery” (as opposed to general muscle growth) is largely theoretical
• Long-term safety implications of myostatin inhibition in humans are not well established

#9. AOD-9604

What is it?

A modified fragment of human growth hormone, studied primarily for fat-metabolism effects.

Why is it being researched for recovery?

Its origin as a growth-hormone fragment has generated some interest in tissue-repair contexts, though the bulk of its research targets metabolic, not structural-repair, endpoints.

What does the research show?

Some human trials have investigated AOD-9604 for metabolic/weight-related outcomes; connective-tissue or recovery-specific human research is much more limited.

What tissues have been studied?

Adipose (fat) tissue primarily; limited direct connective-tissue research.

Human evidence: Yes, for metabolic use not for recovery use specifically.

Evidence level: Level 2–3, but the human evidence that exists doesn’t target recovery as an endpoint

Key limitations:

• “Recovery” framing for AOD-9604 in marketing contexts is a significant extrapolation beyond what the human trials actually studied
• Its research history is more relevant to metabolic peptide discussions than tissue-repair discussions

#10. ARA-290 (Cibinetide)

What is it?

A synthetic peptide derived from erythropoietin, engineered to retain tissue-protective properties without erythropoietin’s blood-cell-stimulating effects.

Why is it being researched for recovery?

Proposed tissue-protective and anti-inflammatory mechanisms have been studied in the context of nerve and vascular tissue protection.

What does the research show?

ARA-290 has been studied in human clinical trials for other indications, including neuropathic pain associated with sarcoidosis giving it comparatively more human trial exposure than most peptides on this list, though not for musculoskeletal recovery specifically.

What tissues have been studied?

Nerve and vascular tissue, in both animal and some human trial contexts.

Human evidence: Yes, in clinical trials but for specific conditions unrelated to sports or musculoskeletal recovery.

Evidence level: Level 3, for its studied indications

Key limitations:

• Human trial data exists but doesn’t address the musculoskeletal “recovery” use case most commonly discussed online
• Availability and regulatory status for research use varies and should be independently confirmed

Peptides Studied for Muscle Recovery

Animal research has investigated BPC-157, TB-500, follistatin-344, and MOTS-c in muscle-related contexts respectively for general tissue repair, cell migration/angiogenesis, myostatin inhibition, and metabolic regulation. None have controlled human trials specifically evaluating muscle recovery from exercise or injury.

Peptides Studied for Tendon Research

BPC-157 has the most tendon-specific animal research among peptides on this list, investigated in rodent tendon-injury models. TB-500 has been studied in broader soft-tissue models that include some tendon-adjacent research. Human tendon-specific clinical trials for either are not established.

Peptides Studied for Ligament Research

BPC-157 again has the most direct ligament-focused animal research. Other peptides on this list have limited or no ligament-specific research; most soft-tissue research (TB-500) doesn’t isolate ligament tissue specifically from other soft tissue.

Peptides Studied for Bone Research

Bone-specific research is thinner across this entire category. BPC-157 has some preclinical bone-healing research in animal models; the other peptides on this list have little to no bone-specific literature most of their tissue research targets soft tissue, skin, or muscle rather than bone.

Peptides Studied for Cartilage Research

Cartilage-specific research is the sparsest category here. None of the peptides on this list have a substantial, dedicated cartilage-research literature comparable to their tendon, muscle, or skin research cartilage effects, where mentioned, are typically inferred from broader tissue-repair mechanisms rather than directly studied.

Peptides Studied for Wound Healing

GHK-Cu has the most developed wound-healing evidence base, particularly for topical/dermatological use. BPC-157, TB-500, and LL-37 all have preclinical wound-model research; LL-37’s antimicrobial properties give it a somewhat distinct role in this category compared to the others.

How Might Recovery Peptides Work?

Researchers have proposed several mechanisms relevant to tissue repair:

• Angiogenesis new blood vessel formation, proposed as a mechanism for BPC-157 and TB-500
• Cellular migration cells moving to an injury site, a proposed function of TB-500’s actin-regulating activity
• Fibroblast activity cells responsible for producing connective tissue, implicated in BPC-157 wound models
• Collagen-related pathways central to GHK-Cu’s proposed mechanism
• Extracellular matrix remodeling the structural scaffold tissue is built on, relevant to GHK-Cu and broader repair research
• Inflammatory signaling modulated by KPV and, more broadly, thymosin alpha-1
• Growth-factor signaling implicated across several of these peptides’ proposed mechanisms
• Cellular stress responses relevant to MOTS-c’s proposed metabolic role

These are proposed and investigated mechanisms research suggests these pathways are involved, not that any specific peptide has been shown to reliably produce a specific clinical outcome in humans.

How Much Human Evidence Exists for Recovery Peptides?

Very little, for the specific “recovery” use case discussed in this article. Animal models are useful because they allow controlled study of injury and healing processes that would be difficult or unethical to induce deliberately in humans. But animal models don’t reliably predict human outcomes species differ in metabolism, immune response, wound-healing physiology, and the injury models themselves are often simplified compared to real-world human injuries.

A treatment that shows strong effects in a rodent tendon-injury model may show a different effect, a weaker effect, or no effect in humans and the only way to know is a properly controlled human trial, which for most peptides on this list doesn’t yet exist for recovery applications specifically.

Promising preclinical findings are a reason for further research, not a substitute for it.

Are Recovery Peptides FDA Approved?

No compound on this list is FDA-approved for tissue repair, recovery, or regenerative use. A few distinctions matter here:

• FDA-approved drugs go through a formal review process demonstrating safety and efficacy for a specific indication none of these peptides have this for recovery use
• Investigational compounds are being studied under a formal regulatory pathway toward possible approval most peptides here aren’t in this category for recovery applications either
• Compounded drugs are prepared by compounding pharmacies under a different regulatory framework than FDA-approved drugs; several peptides on this list (BPC-157, TB-500, KPV, MOTS-c, GHK-Cu) appear on the FDA’s Category 2 bulk drug substances list for compounding, with regulatory status shifting through 2026
• Research-use-only products are sold for laboratory research, explicitly not for human use, and haven’t been FDA-evaluated for human consumption
• Dietary supplements and cosmetic products follow yet another regulatory framework GHK-Cu’s topical/cosmetic formulations fall here, distinct from injectable use

Don’t assume any peptide is FDA-approved unless verified against current FDA sources and don’t assume regulatory review or discussion (like a compounding advisory committee meeting) equals approval or endorsement.

What Does Research Use Only Mean?

“Research Use Only” (RUO) is a labeling category indicating a product is intended for laboratory or analytical research, not human or animal consumption. It does not mean the product has been evaluated by the FDA for safety in humans, and it does not mean the underlying research supports therapeutic effectiveness. RUO labeling is a statement about intended use and regulatory category not a safety or efficacy claim.

Are Recovery Peptides Safe?

Safety depends on the specific peptide, route of administration, formulation, purity, and duration of exposure it’s not a single yes/no answer across this entire category. It’s also worth separating two different statements that sound similar but aren’t:

• “No safety concerns were observed in this particular animal study” a narrow, study-specific finding
• “This peptide is proven safe” a much broader claim that current evidence doesn’t support for most peptides on this list

FDA reviews of BPC-157 and related compounds have specifically flagged insufficient human safety data, potential immunogenicity, and peptide-related impurity concerns as open questions not as resolved, favorable findings.

Regulatory and Quality Risks

Beyond the underlying research questions, buyers of research-labeled peptide products face separate quality and sourcing risks: unverified purity claims, missing batch/lot information, generic (non-batch-specific) COAs, unclear or undisclosed testing laboratories, and most importantly for this article’s purpose products marketed with medical claims that outrun the actual evidence. See our guide to what a peptide COA should actually contain for what to check. None of this is an accusation against any specific supplier; it’s a general caution relevant to how RUO peptide products are marketed across the industry.

How to Evaluate Recovery Peptide Research

• Study design was it a cell study, an animal study, an observational study, or a randomized controlled trial? Each carries different weight.
• Sample size how many subjects (or animals) were studied? Small samples produce less reliable findings.
• Control group was there a meaningful comparison group, or just an uncontrolled before/after observation?
• Outcome was the measured outcome biologically interesting, or clinically meaningful (i.e., something that would actually matter to a patient)?
• Replication has an independent research group reproduced the finding, or does it rest on a single study?
• Publication quality was it peer-reviewed, and in what journal?
• Human relevance does the animal model actually resemble the human injury or condition being discussed?
• Safety did the study evaluate safety at all, or only the outcome of interest?

Research vs. Marketing Claims

Scientific Evidence	Marketing Claim
Animal study showed reduced healing time in a rodent tendon model	“Peptide heals injuries”
Cellular study investigated fibroblast migration	“Regenerates tissue”
Early human study reported a specific, limited outcome	“Clinically proven”
Researchers proposed a mechanism based on animal data	“Guaranteed recovery”

These pairs are not equivalent. A specific, limited scientific finding does not license a broad, unqualified marketing claim and content (including this article) should be read skeptically whenever it collapses that distinction.

Common Myths About Recovery Peptides

Myth 1: More research means proven effectiveness. A large volume of animal studies still doesn’t establish human effectiveness volume and quality/human-relevance are different things.

Myth 2: A high purity percentage proves clinical safety. Purity tells you what’s in the vial, not whether the compound is safe or effective for any particular use.

Myth 3: Animal research proves human effectiveness. Animal models are a starting point for hypotheses, not a substitute for human trials physiological differences between species are substantial.

Myth 4: Research-use-only means safe for human use. RUO labeling is a regulatory and intended-use category, not a safety endorsement RUO products explicitly haven’t been evaluated for human use.

Myth 5: A COA means a peptide is FDA approved. A Certificate of Analysis documents purity/identity testing results for a specific batch it says nothing about FDA approval status.

Myth 6: A peptide marketed for recovery has been clinically proven. Marketing language and scientific evidence are frequently mismatched in this category check the underlying research yourself rather than taking a product description’s word for it.

Frequently Asked Questions

What are the best recovery peptides for research?

BPC-157, TB-500, GHK-Cu, KPV, LL-37, MOTS-c, and thymosin alpha-1 have the most research interest and volume in 2026, though “best” here reflects research activity, not proven clinical effectiveness.

What are recovery peptides?

An informal term for peptides investigated in processes related to tissue repair, inflammation, and regeneration not an established medical or regulatory category.

What is BPC-157 being researched for?

Tendon, ligament, muscle, gut, and nerve tissue repair in animal models, with proposed mechanisms involving angiogenesis and growth-factor signaling.

What is TB-500 being researched for?

Soft-tissue repair and wound healing in animal models, with proposed mechanisms involving cell migration and angiogenesis linked to its relationship to thymosin beta-4.

What is thymosin beta-4?

A naturally occurring protein involved in cell structure and movement; TB-500 is a synthesized fragment related to it, though the two terms aren’t always used interchangeably in the literature.

What is GHK-Cu research focused on?

Primarily skin and collagen-related research (well-developed for topical use); injectable use for broader tissue repair has a much thinner evidence base.

Which peptides are studied for tendon recovery?

BPC-157 has the most tendon-specific animal research among commonly discussed recovery peptides; human tendon-specific clinical trials aren’t established for any of them.

Which peptides are studied for muscle recovery?

BPC-157, TB-500, follistatin-344, and MOTS-c all have some muscle-related animal research, through different proposed mechanisms.

Which peptides are studied for wound healing?

GHK-Cu has the most developed wound-healing evidence, particularly topically; BPC-157, TB-500, and LL-37 also have preclinical wound-model research.

Are recovery peptides proven to work in humans?

No, not in the sense of established clinical evidence most research on this list is preclinical (animal or cell-based), with very limited human clinical data for recovery-specific applications.

Are recovery peptides FDA approved?

No peptide discussed in this article is FDA-approved for tissue repair or recovery use; several have been reviewed as bulk substances for compounding, which is a different regulatory category than approval.

What is the difference between preclinical and clinical peptide research?

Preclinical research is conducted in cells or animals; clinical research is conducted in human subjects. Preclinical findings often don’t translate directly to human outcomes.

What does research use only mean?

It means a product is labeled and intended for laboratory research, not human or animal use, and hasn’t been FDA-evaluated for human consumption.

Does a peptide COA prove safety?

No a Certificate of Analysis documents purity and identity testing for a specific batch, not safety or efficacy for any use.

Does peptide purity prove effectiveness?

No purity indicates what’s in the vial, not whether the compound produces any particular effect in the body.

Are recovery peptides safe?

It depends on the specific peptide, route, formulation, and purity current human safety data for most peptides in this category is limited, and regulatory reviews have flagged specific safety concerns for several of them.

Why are animal studies not enough to prove effectiveness?

Species differ in metabolism, immune response, and injury physiology a result in an animal model doesn’t reliably predict the same result in humans.

How can I evaluate peptide research?

Look at study design, sample size, presence of a control group, whether the outcome was clinically meaningful, whether findings have been replicated, and whether the study addressed safety.

What are the biggest red flags in peptide marketing?

Claims like “clinically proven,” “guaranteed recovery,” or “heals injuries” that aren’t backed by the level of human evidence those phrases imply.

Are recovery peptides legal?

Regulatory status varies by peptide and has been actively shifting in 2026 several are under FDA compounding review. This is not legal advice; confirm current status for the specific peptide and use case in question.

Key Takeaways

• BPC-157 and TB-500 have the largest bodies of preclinical (animal) research among commonly discussed recovery peptides, but very limited human clinical evidence for tissue-repair use
• GHK-Cu’s evidence is strongest for topical/cosmetic use; injectable use for broader recovery has a much thinner evidence base
• KPV, LL-37, MOTS-c, follistatin-344, AOD-9604, and ARA-290 each have narrower or more indirect research support for the “recovery” use case specifically
• Most evidence across this entire category is preclinical animal or cell-based, not established human clinical evidence
• None of these peptides are FDA-approved for tissue repair or recovery use; several are under active regulatory review as compounding bulk substances
• FDA reviews of several of these compounds have specifically flagged insufficient human safety data as an open concern, not a resolved question
• Research-use-only labeling reflects intended use and regulatory category not a safety or efficacy claim
• Evaluate any specific claim by checking study design, sample size, human relevance, and whether it was actually studying the outcome being claimed